Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 17764010)

  • 1. Vgamma9Vdelta2 T cell-mediated recognition of human solid tumors. Potential for immunotherapy of hepatocellular and colorectal carcinomas.
    Bouet-Toussaint F; Cabillic F; Toutirais O; Le Gallo M; Thomas de la Pintière C; Daniel P; Genetet N; Meunier B; Dupont-Bierre E; Boudjema K; Catros V
    Cancer Immunol Immunother; 2008 Apr; 57(4):531-9. PubMed ID: 17764010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aminobisphosphonate-pretreated dendritic cells trigger successful Vgamma9Vdelta2 T cell amplification for immunotherapy in advanced cancer patients.
    Cabillic F; Toutirais O; Lavoué V; de La Pintière CT; Daniel P; Rioux-Leclerc N; Turlin B; Mönkkönen H; Mönkkönen J; Boudjema K; Catros V; Bouet-Toussaint F
    Cancer Immunol Immunother; 2010 Nov; 59(11):1611-9. PubMed ID: 20582413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphostim-activated gamma delta T cells kill autologous metastatic renal cell carcinoma.
    Viey E; Fromont G; Escudier B; Morel Y; Da Rocha S; Chouaib S; Caignard A
    J Immunol; 2005 Feb; 174(3):1338-47. PubMed ID: 15661891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNAX accessory molecule-1 (CD226) promotes human hepatocellular carcinoma cell lysis by Vgamma9Vdelta2 T cells.
    Toutirais O; Cabillic F; Le Friec G; Salot S; Loyer P; Le Gallo M; Desille M; de La Pintière CT; Daniel P; Bouet F; Catros V
    Eur J Immunol; 2009 May; 39(5):1361-8. PubMed ID: 19404979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ex vivo characterization of γδ T-cell repertoire in patients after adoptive transfer of Vγ9Vδ2 T cells expressing the interleukin-2 receptor β-chain and the common γ-chain.
    Izumi T; Kondo M; Takahashi T; Fujieda N; Kondo A; Tamura N; Murakawa T; Nakajima J; Matsushita H; Kakimi K
    Cytotherapy; 2013 Apr; 15(4):481-91. PubMed ID: 23391461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. V gamma 9V delta 2 T cell response to colon carcinoma cells.
    Corvaisier M; Moreau-Aubry A; Diez E; Bennouna J; Mosnier JF; Scotet E; Bonneville M; Jotereau F
    J Immunol; 2005 Oct; 175(8):5481-8. PubMed ID: 16210656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lysis of a broad range of epithelial tumour cells by human gamma delta T cells: involvement of NKG2D ligands and T-cell receptor- versus NKG2D-dependent recognition.
    Wrobel P; Shojaei H; Schittek B; Gieseler F; Wollenberg B; Kalthoff H; Kabelitz D; Wesch D
    Scand J Immunol; 2007; 66(2-3):320-8. PubMed ID: 17635809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allogeneic Vγ9Vδ2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer.
    Xu Y; Xiang Z; Alnaggar M; Kouakanou L; Li J; He J; Yang J; Hu Y; Chen Y; Lin L; Hao J; Li J; Chen J; Li M; Wu Q; Peters C; Zhou Q; Li J; Liang Y; Wang X; Han B; Ma M; Kabelitz D; Xu K; Tu W; Wu Y; Yin Z
    Cell Mol Immunol; 2021 Feb; 18(2):427-439. PubMed ID: 32939032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD94/NKG2 inhibitory receptor complex modulates both anti-viral and anti-tumoral responses of polyclonal phosphoantigen-reactive V gamma 9V delta 2 T lymphocytes.
    Poccia F; Cipriani B; Vendetti S; Colizzi V; Poquet Y; Battistini L; López-Botet M; Fournié JJ; Gougeon ML
    J Immunol; 1997 Dec; 159(12):6009-17. PubMed ID: 9550399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-21-mediated potentiation of antitumor cytolytic and proinflammatory responses of human V gamma 9V delta 2 T cells for adoptive immunotherapy.
    Thedrez A; Harly C; Morice A; Salot S; Bonneville M; Scotet E
    J Immunol; 2009 Mar; 182(6):3423-31. PubMed ID: 19265120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy and zoledronate sensitize solid tumour cells to Vgamma9Vdelta2 T cell cytotoxicity.
    Mattarollo SR; Kenna T; Nieda M; Nicol AJ
    Cancer Immunol Immunother; 2007 Aug; 56(8):1285-97. PubMed ID: 17265022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lysis of aminobisphosphonate-sensitized MCF-7 breast tumor cells by Vγ9Vδ2 T cells.
    Dhar S; Chiplunkar SV
    Cancer Immun; 2010 Nov; 10():10. PubMed ID: 21069948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemokine receptors expression and migration potential of tumor-infiltrating and peripheral-expanded Vgamma9Vdelta2 T cells from renal cell carcinoma patients.
    Viey E; Lucas C; Romagne F; Escudier B; Chouaib S; Caignard A
    J Immunother; 2008 Apr; 31(3):313-23. PubMed ID: 18317356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expansion With IL-15 Increases Cytotoxicity of Vγ9Vδ2 T Cells and Is Associated With Higher Levels of Cytotoxic Molecules and T-bet.
    Aehnlich P; Carnaz Simões AM; Skadborg SK; Holmen Olofsson G; Thor Straten P
    Front Immunol; 2020; 11():1868. PubMed ID: 32983105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expansion of human peripheral blood γδ T cells using zoledronate.
    Kondo M; Izumi T; Fujieda N; Kondo A; Morishita T; Matsushita H; Kakimi K
    J Vis Exp; 2011 Sep; (55):. PubMed ID: 21931292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours.
    Nicol AJ; Tokuyama H; Mattarollo SR; Hagi T; Suzuki K; Yokokawa K; Nieda M
    Br J Cancer; 2011 Sep; 105(6):778-86. PubMed ID: 21847128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
    Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-Density Lipoprotein Uptake Inhibits the Activation and Antitumor Functions of Human Vγ9Vδ2 T Cells.
    Rodrigues NV; Correia DV; Mensurado S; Nóbrega-Pereira S; deBarros A; Kyle-Cezar F; Tutt A; Hayday AC; Norell H; Silva-Santos B; Dias S
    Cancer Immunol Res; 2018 Apr; 6(4):448-457. PubMed ID: 29358174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatocellular carcinoma cell sensitivity to Vγ9Vδ2 T lymphocyte-mediated killing is increased by zoledronate.
    Sugai S; Yoshikawa T; Iwama T; Tsuchiya N; Ueda N; Fujinami N; Shimomura M; Zhang R; Kaneko S; Uemura Y; Nakatsura T
    Int J Oncol; 2016 May; 48(5):1794-804. PubMed ID: 26936487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expanded and Activated Natural Killer Cells for Immunotherapy of Hepatocellular Carcinoma.
    Kamiya T; Chang YH; Campana D
    Cancer Immunol Res; 2016 Jul; 4(7):574-81. PubMed ID: 27197065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.